New GERD drug aims to keep esophagus healed, but trial never started
NCT ID NCT07313774
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to see if a new drug called linaprazan glurate could keep the esophagus healed in people with GERD-related erosive esophagitis, compared to an existing drug (lansoprazole). Participants would have taken daily pills for up to 52 weeks and had regular camera exams of their throat. However, the trial was withdrawn before any participants were enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EROSIVE ESOPHAGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill prevent esophageal damage from returning?
- Smart bottle cap could reveal hidden missed doses in GERD patients
- Could a simple liquid barrier help nighttime heartburn sufferers sleep better?
- New GERD drug tegoprazan tested in large real-world study
- New GERD drug aims to heal esophagus damage when standard treatments fail
- Can a diet and lifestyle program replace acid reflux pills after achalasia surgery?